肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

PNAS：科学家测试新抗黑色素瘤癌症疫苗

2018-09-26 佚名 生物通

黑色素瘤疫苗进展
关注

科学家最近在《美国国家科学院院刊》（PNAS）上报道，一种增强免疫系统抗癌能力的、实验性的癌症疫苗可以与其他癌症疗法协同作用来抗击侵袭性肿瘤。

科学家最近在《美国国家科学院院刊》（PNAS）上报道，一种增强免疫系统抗癌能力的、实验性的癌症疫苗可以与其他癌症疗法协同作用来抗击侵袭性肿瘤。研究人员证明，将一种名为Diprovocim的分子添加到疫苗中可以将抗癌细胞吸引到肿瘤部位。他们在患有黑色素瘤的小鼠身上的实验表明，这些加了Diprovocim的疫苗能在单独药物治疗无效的情况下提高康复的机会。与德州大学西南分校诺贝尔奖得主Bruce Beutler一起领导该项研究的斯克里普斯研究所教授Dale Boger博士说：“这种联合疗法在治疗黑色素瘤方面产生了一种完全的反应，一种治愈性的反应。” 这种联合疫苗还促使免疫系统在肿瘤细胞复发时与它们进行抗争，这种能力可以防止癌症复发。“正如疫苗可以训练身体抵御外部病原体一样，这种疫苗训练免疫系统去追踪肿瘤。”Boger博士解释说。由Boger和Beutler开发，Diprovocim作为一种“佐剂”起作用，这种分子被添加到疫苗中以激发机体的免疫反应。该分子在实验室中易于合成，且易于修饰，使其在医学上具有吸引力。这项新研究表明，向癌症疫苗中添加Diprovocim可以产生显著的效果。研究人员在一

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1680562, encodeId=d8d21680562b4, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Thu Feb 07 16:42:00 CST 2019, time=2019-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1856216, encodeId=630418562166f, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Sep 05 08:42:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558928, encodeId=c9be155892877, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Sep 28 08:42:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564937, encodeId=1ca3156493e15, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Sep 28 08:42:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346935, encodeId=f8793469353a, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Sep 27 17:48:58 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346897, encodeId=4d7334689eac, content=学习了，收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8e425737, createdName=tw007007, createdTime=Thu Sep 27 10:52:47 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346834, encodeId=5bdc346834f6, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Sep 26 22:22:38 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346818, encodeId=ff6034681896, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Sep 26 21:11:13 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346811, encodeId=4c013468119a, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Wed Sep 26 21:04:20 CST 2018, time=2018-09-26, status=1, ipAttribution=)]
    2019-02-07 sunylz

    #色素#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1680562, encodeId=d8d21680562b4, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Thu Feb 07 16:42:00 CST 2019, time=2019-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1856216, encodeId=630418562166f, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Sep 05 08:42:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558928, encodeId=c9be155892877, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Sep 28 08:42:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564937, encodeId=1ca3156493e15, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Sep 28 08:42:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346935, encodeId=f8793469353a, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Sep 27 17:48:58 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346897, encodeId=4d7334689eac, content=学习了，收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8e425737, createdName=tw007007, createdTime=Thu Sep 27 10:52:47 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346834, encodeId=5bdc346834f6, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Sep 26 22:22:38 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346818, encodeId=ff6034681896, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Sep 26 21:11:13 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346811, encodeId=4c013468119a, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Wed Sep 26 21:04:20 CST 2018, time=2018-09-26, status=1, ipAttribution=)]
    2019-09-05 drwjr

    #PNAS#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1680562, encodeId=d8d21680562b4, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Thu Feb 07 16:42:00 CST 2019, time=2019-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1856216, encodeId=630418562166f, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Sep 05 08:42:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558928, encodeId=c9be155892877, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Sep 28 08:42:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564937, encodeId=1ca3156493e15, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Sep 28 08:42:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346935, encodeId=f8793469353a, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Sep 27 17:48:58 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346897, encodeId=4d7334689eac, content=学习了，收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8e425737, createdName=tw007007, createdTime=Thu Sep 27 10:52:47 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346834, encodeId=5bdc346834f6, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Sep 26 22:22:38 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346818, encodeId=ff6034681896, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Sep 26 21:11:13 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346811, encodeId=4c013468119a, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Wed Sep 26 21:04:20 CST 2018, time=2018-09-26, status=1, ipAttribution=)]
    2018-09-28 cqlidoudou

    #黑色素#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1680562, encodeId=d8d21680562b4, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Thu Feb 07 16:42:00 CST 2019, time=2019-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1856216, encodeId=630418562166f, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Sep 05 08:42:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558928, encodeId=c9be155892877, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Sep 28 08:42:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564937, encodeId=1ca3156493e15, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Sep 28 08:42:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346935, encodeId=f8793469353a, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Sep 27 17:48:58 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346897, encodeId=4d7334689eac, content=学习了，收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8e425737, createdName=tw007007, createdTime=Thu Sep 27 10:52:47 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346834, encodeId=5bdc346834f6, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Sep 26 22:22:38 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346818, encodeId=ff6034681896, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Sep 26 21:11:13 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346811, encodeId=4c013468119a, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Wed Sep 26 21:04:20 CST 2018, time=2018-09-26, status=1, ipAttribution=)]
    2018-09-28 cqlidoudou

    #黑色素#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1680562, encodeId=d8d21680562b4, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Thu Feb 07 16:42:00 CST 2019, time=2019-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1856216, encodeId=630418562166f, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Sep 05 08:42:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558928, encodeId=c9be155892877, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Sep 28 08:42:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564937, encodeId=1ca3156493e15, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Sep 28 08:42:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346935, encodeId=f8793469353a, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Sep 27 17:48:58 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346897, encodeId=4d7334689eac, content=学习了，收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8e425737, createdName=tw007007, createdTime=Thu Sep 27 10:52:47 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346834, encodeId=5bdc346834f6, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Sep 26 22:22:38 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346818, encodeId=ff6034681896, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Sep 26 21:11:13 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346811, encodeId=4c013468119a, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Wed Sep 26 21:04:20 CST 2018, time=2018-09-26, status=1, ipAttribution=)]
    2018-09-27 kafei

    学习了谢谢

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1680562, encodeId=d8d21680562b4, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Thu Feb 07 16:42:00 CST 2019, time=2019-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1856216, encodeId=630418562166f, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Sep 05 08:42:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558928, encodeId=c9be155892877, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Sep 28 08:42:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564937, encodeId=1ca3156493e15, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Sep 28 08:42:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346935, encodeId=f8793469353a, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Sep 27 17:48:58 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346897, encodeId=4d7334689eac, content=学习了，收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8e425737, createdName=tw007007, createdTime=Thu Sep 27 10:52:47 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346834, encodeId=5bdc346834f6, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Sep 26 22:22:38 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346818, encodeId=ff6034681896, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Sep 26 21:11:13 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346811, encodeId=4c013468119a, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Wed Sep 26 21:04:20 CST 2018, time=2018-09-26, status=1, ipAttribution=)]
    2018-09-27 tw007007

    学习了，收藏

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1680562, encodeId=d8d21680562b4, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Thu Feb 07 16:42:00 CST 2019, time=2019-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1856216, encodeId=630418562166f, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Sep 05 08:42:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558928, encodeId=c9be155892877, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Sep 28 08:42:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564937, encodeId=1ca3156493e15, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Sep 28 08:42:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346935, encodeId=f8793469353a, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Sep 27 17:48:58 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346897, encodeId=4d7334689eac, content=学习了，收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8e425737, createdName=tw007007, createdTime=Thu Sep 27 10:52:47 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346834, encodeId=5bdc346834f6, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Sep 26 22:22:38 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346818, encodeId=ff6034681896, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Sep 26 21:11:13 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346811, encodeId=4c013468119a, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Wed Sep 26 21:04:20 CST 2018, time=2018-09-26, status=1, ipAttribution=)]
    2018-09-26 1e1b8538m79(暂无匿称)

    不错的文章值得拥有哦

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1680562, encodeId=d8d21680562b4, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Thu Feb 07 16:42:00 CST 2019, time=2019-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1856216, encodeId=630418562166f, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Sep 05 08:42:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558928, encodeId=c9be155892877, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Sep 28 08:42:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564937, encodeId=1ca3156493e15, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Sep 28 08:42:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346935, encodeId=f8793469353a, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Sep 27 17:48:58 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346897, encodeId=4d7334689eac, content=学习了，收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8e425737, createdName=tw007007, createdTime=Thu Sep 27 10:52:47 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346834, encodeId=5bdc346834f6, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Sep 26 22:22:38 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346818, encodeId=ff6034681896, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Sep 26 21:11:13 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346811, encodeId=4c013468119a, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Wed Sep 26 21:04:20 CST 2018, time=2018-09-26, status=1, ipAttribution=)]
    2018-09-26 医者仁心5538

    学习了

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1680562, encodeId=d8d21680562b4, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Thu Feb 07 16:42:00 CST 2019, time=2019-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1856216, encodeId=630418562166f, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Sep 05 08:42:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558928, encodeId=c9be155892877, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Sep 28 08:42:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564937, encodeId=1ca3156493e15, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Fri Sep 28 08:42:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346935, encodeId=f8793469353a, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Sep 27 17:48:58 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346897, encodeId=4d7334689eac, content=学习了，收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c8e425737, createdName=tw007007, createdTime=Thu Sep 27 10:52:47 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346834, encodeId=5bdc346834f6, content=不错的文章值得拥有哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed Sep 26 22:22:38 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346818, encodeId=ff6034681896, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Sep 26 21:11:13 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346811, encodeId=4c013468119a, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Wed Sep 26 21:04:20 CST 2018, time=2018-09-26, status=1, ipAttribution=)]
    2018-09-26 一天没事干

    很好的学习机会

    0

相关资讯

CLIN CANCER RES：PHIP拷贝数作为皮肤黑色素瘤的预后及进展标志

之前的研究表明PHIP在调节黑色素瘤转移的过程中发挥了重要作用。CLIN CANCER RES近期发表了一篇文章，研究PHIP拷贝数在黑色素瘤进展中的作用。

PNAS重磅：100%的黑色素瘤完全消失！只需这两种药物联合使用！

成功的癌症免疫疗法需要激活先天免疫受体以促进树突细胞（DC）成熟，抗原呈递，共刺激分子的上调和细胞因子分泌，最终诱导肿瘤抗原特异性细胞毒性T淋巴细胞（CTL）的活化，达到杀灭肿瘤的效果。一次偶然的化学合成产生了一种名为Diprovocim化合物，由于其特殊的药理效应引起了德克萨斯大学西南医学中心Bruce Beutler研究团队的注意，接下来的研究发现这种药物作为Toll样受体（TLR）1 / T

身上有胎记和痣？这些你需要警惕了

近日，河南20岁小伙魏尚子因一片胎记住院，医生说是“癌”。帅气的魏尚子新婚不久，右肩部那颗“蝇子屎”大小的胎记自出生起就陪伴着他，不痛不痒从来没有在意过，但自去年开始，这颗伴随着他成长的胎记竟开始疯狂生长，从豆粒大小到如今鸡蛋一般大，且发作起来后牵动全身都疼痛难忍，无奈之下只得住进了郑州的大医院。

Lancet oncol：Encorafenib联合binimetinib治疗BRAF突变型黑色素瘤总体存活率效益显著

COLUMBUS试验研究encorafenib联合binimetinib和单独应用encorafenib对比vemurafenib用于携带BRAF[V600]突变的黑色素瘤患者提高无进展存活期的效果。现研究人员对总体存活率的次要结点结果进行汇总。COLUMBUS试验是在28个国家的162家医院中进行的包含两部分的随机的、开放性的3期研究，招募年满18岁的病理确诊的局部晚期不可手术切除的或已转移的皮

CLIN CANCER RES：抗CTLA4治疗对过继TIL疗法治疗转移性黑色素瘤患者的影响

使用肿瘤浸润淋巴细胞进行过继细胞治疗在转移性黑色素瘤患者中均有临床疗效。近年来免疫检查点抑制剂得到广泛应用，其对肿瘤浸润淋巴细胞过继治疗的影响以及两种治疗方案的合理顺序尚需探索。CLIN CANCER RES近期发表了一篇文章研究这一问题。

Braftovi/Mektovi联合欧洲获批用于治疗BRAFV600突变的不可切除或转移性黑色素瘤

欧洲委员会（EC）已批准Pierre Fabre公司的Braftovi/Mektovi联合疗法上市，用于治疗BRAFV600突变的不可切除或转移性黑色素瘤成人患者。